Consultation opens for updated NICE guideline on CKD
The use of sodium-glucose co-transporter-2 (SGLT2) inhibitors in type 2 diabetes if albuminuria is greater than 30mg/mmol is a key change in the newly amended NICE guidance for Chronic Kidney Disease (CKD).
The consultation process for the changes has opened and clinicians are being encouraged to pass on their views to a stakeholder organisation. They have until 19 March, 2021 to complete their submission.
The guideline covers the care and treatment of people with, or at risk of developing, chronic kidney disease. It aims to prevent or delay the progression, reduce the risk of complications and cardiovascular disease.
It also includes information on managing anaemia associated with chronic kidney disease and hyperphosphataemia in people with chronic kidney disease.
The recommendations were largely developed before the COVID-19 pandemic so contributors have been asked to supply any particular issues relating to the pandemic that they think should be take into account when finalising the guideline for publication.
To review the document, click here.